IVD Manufacturing Record Dossier: Evidence and Retrieval

An IVD Manufacturing Record Dossier, as used here, is an optional index connecting a particular manufacturing history to its supporting records. Its purpose is not to collect the largest possible folder. It is to let another person reconstruct a defined chain, distinguish evidence from assertions, and find the decisions that remain outstanding. The index points to records; it does not replace them or turn their presence into approval.

This exercise follows one reagent lot, two additional component lots, one kit lot, an assigned packaging revision and a shipment reference. It deliberately leaves three problems unresolved: an unexplained component-count difference, a missing dating-review reference and a mismatched label revision. The useful outcome is an accurate account of those gaps, not a declaration that the kit can be released.

The legal scope must be established separately. Under 21 CFR 820.1, Part 820 governs specified activities involving finished devices intended for human use. A manufacturer performing only some covered operations need comply with the requirements applicable to those operations. The section excludes manufacturers of components or parts of finished devices from its provisions. Do not infer an entity's scope merely from its position in this example's component chain; assess the product and the operations actually performed.

For the wider manufacturing sequence, use the Diagnostic Kit & Reagent Manufacturing Guide. This companion concentrates on evidence relationships, source ownership and handover rather than repeating receiving, formulation, testing or manufacturing instructions.

The fictional kit lot K-261016 contains three separately counted items per kit: one filled reagent vial from R-261014, one plate from component lot PL-610 and one control vial from component lot CT-611. Assembly record AR-144 reports 240 assembled kits. Configuration assignment CA-144 identifies packaging specification PK-07 Rev D and its associated label artwork LBL-07 Rev D. These identifiers belong to this exercise only.

Shipment reference SH-144 is a draft allocation for 180 kits, not an executed shipment. The other 60 kits are unallocated. All 240 assembled kits remain on hand in the example, pending a separate disposition decision. This distinction matters: a reference that is usable for a planning question may be unusable for proving dispatch.

For applicable IVD labels, 21 CFR 809.10(a)(9) requires a lot or control number from which the complete manufacturing history can be determined. Its qualifications are specific: a multiple-unit product's number must permit tracing individual-unit identities; an instrument's number must permit tracing all functional subassemblies; and included units used together as a system should share the same lot or control number, if appropriate, or use other suitable uniform identification. Paragraph (a)'s applicability qualifications still apply.

The proposed index is one way to navigate relevant records, not a claim that this three-item illustration establishes a complete manufacturing history. Record each relationship explicitly: an item was issued to a kit lot, a revision was assigned to an operation, or a shipment reference allocated a quantity. A shared filename or a matching date alone does not establish that relationship.

Start by defining the question each index entry should answer. Expected means the exercise calls for that evidence under its stated scope; it is not a new statutory requirement. Retrieved means the identified record can actually be opened and read. Usable means its identity, revision, scope and contents support the particular proposition being assessed. These are different tests.

For example, SR-52 Rev 2 can be retrieved and identified as a study report without establishing that someone approved its application to the dating and storage statements assigned to K-261016. Similarly, LI-144 can be useful evidence of a revision discrepancy while remaining unusable as evidence that the assigned label was correctly applied. Do not hide this distinction inside a single green status.

Keep the same row IDs when separating retrieval details from ownership and interpretation. This lets a handover note say E07 remains unresolved without relying on a page number that changes when the dossier is exported. The following table describes usability only for this exercise; it does not approve the underlying records.

Ten of the twelve entries contain retrievable material. That count is not a readiness score: the missing and contradictory entries concern different questions and cannot be averaged away. Preserve the scope limitation beside the record. A reviewer should not have to discover, several links later, that an apparently complete row supports only identity rather than a decision.

For each reference, retain a stable source location, record identifier, revision or relevant date, applicable lot, owner and exception or decision link. These are suggested fields, not mandated dossier columns. If a source contains several lots, identify the page, entry or section connecting it to K-261016. A document title without the relevant relationship is an unresolved cross-reference.

The assigned revision is the starting point, not a conclusion about what happened. CA-144 calls for PK-07 Rev D and LBL-07 Rev D. LR-144 records release of LBL-07 Rev D for use. Yet retained sample LS-144 identifies LBL-07 Rev C, and LI-144 points to that sample. Those records disagree about the revision associated with the packaging operation.

Under 21 CFR 820.45(a), labeling and packaging must be examined for accuracy before release or storage where applicable, including device identification, expiration date, storage instructions, handling instructions and additional processing instructions. Paragraph (b) addresses documented release of labeling for use. Paragraph (c) addresses operations to prevent mixups, inspection before use and documentation of labeling-inspection results. These are labeling and packaging controls; a label-release record is not a finished-product disposition decision.

For the exercise, open EX-32 against E07 and preserve both revisions as evidence. Ask whether LS-144 is the actual retained sample, an incorrectly associated sample, or evidence of an unrecorded revision departure. Each possibility calls for supporting records. Do not choose the most convenient explanation, change the index to Rev D, or treat the release of Rev D as proof that Rev D was used.

Accompanying Labeling Is a Separate Reference

21 CFR 809.10(b)(15) specifies the identified date of issuance of the last revision for accompanying labeling. Apply paragraph (b)'s scope: it addresses labeling accompanying each product, such as a package insert, except where information is inapplicable or a product-class standard specifies otherwise. It also provides special allowances for certain multiple-purpose diagnostic instruments and replacement reagents. This is not a universal instruction to put a revision date on every manufacturing label.

E08 therefore points separately to IFU-07 Rev D, issued 2026-09-30. That retrieved insert does not resolve the mismatch in LS-144. A correct document in one labeling category cannot substitute for evidence about another. If someone proposes that Rev C was an authorized alternative, request the applicable authorization and its scope; no such authorization has been retrieved here.

RC-144 compares issued physical items with their documented destinations. Each assembled kit accounts for one reagent vial, one plate and one control vial. Returned items are unused items returned from the operation; rejected items have a recorded rejection reason. No sampling allocation is included in this fictional exercise. These quantities are not study sample sizes, statutory tolerances or acceptance criteria.

The reagent row balances because 250 − (240 + 6 + 4) = 0. The plate row does not: 246 − (240 + 4 + 1) = 1. The control row balances because 248 − (240 + 5 + 3) = 0. Across all three rows, 744 issued items equal 720 assembled items, 15 returned items, eight rejected items and one unexplained item. The 720 assembled items are 240 kits × three counted items, not 720 kits.

The recorded rejection reasons are four leaking reagent vials, one damaged plate and three cracked control vials. The returns point to unused quantities recorded at the operation's end. These explanations make the arithmetic interpretable, but the exercise does not independently establish their adequacy. The remaining PL-610 unit has no recorded destination. Do not silently add it to rejection, call it rounding or offset it against another lot.

EX-31 asks the materials and production owners to compare issue, return, assembly and rejection entries for PL-610. A later explanation needs a supporting record and a reasoned assessment of what changed. Until then, the correct result is one unexplained plate—not a balanced reconciliation with a guessed reason.

Keep kit allocation arithmetic separate. SH-144's 180 allocated kits plus 60 unallocated kits equal the 240 kits on hand. That planning balance neither explains the extra issued plate nor proves dispatch. Mixing item counts, kit counts and shipment allocations can make unrelated totals appear to resolve each other.

A report reference and a dating decision answer different questions. SR-52 Rev 2 establishes which report was retrieved. DR-144 is the expected reference connecting the applicable evidence, product configuration and proposed dating and storage statements. CA-144 refers to DR-144, but the review itself cannot be retrieved. E10 therefore remains missing, with EX-33 identifying the unresolved cross-reference.

For reagents, 21 CFR 809.10(a)(5) requires appropriate storage instructions adequate to protect product stability. Where applicable, these include temperature, light, humidity and other pertinent factors, and appropriate instructions for reconstituted or mixed product stored in the original container. The stated basis is reliable, meaningful and specific test methods.

Section 809.10(a)(6) requires a means of assurance at use for the product as provided and any resulting reconstituted or mixed product. It specifies one or more label means: an expiration date based on stated storage instructions, an observable indication of unacceptable alteration, or instructions for a simple method of determining whether the product meets its appropriate standards. Expiry is therefore not the sole option in this provision.

For this dossier, retrieve the exact statement being supported and the decision linking it to the relevant report. Ask whether the decision addresses the product configuration, storage conditions and condition of use actually represented by the labeling. These are retrieval questions, not instructions for designing a stability study. No shelf life is assigned in this example, and no earliest-input-expiry rule is imposed.

A report bearing a suitable title cannot answer those questions by itself. Nor can a dating value copied into a label field demonstrate who evaluated its basis. Record what is known: SR-52 Rev 2 is present; DR-144 is absent; application of the report to this kit's statements remains unresolved. The dating decision owner receives that precise question rather than a vague request to complete the stability folder.

If EU technical documentation is within the product's scope, keep its stability references in a separately identified branch. IVDR Annex II, Section 6.3 addresses claimed shelf life, in-use stability and shipping stability, excluding specimen stability. Its study scopes should not be transferred into this U.S. manufacturing example as universal sample counts.

Specifically, Annex II, Section 6.3.1 requires at least three different lots manufactured under conditions essentially equivalent to routine production; they need not be consecutive. Accelerated studies or extrapolated real-time data are acceptable for initial shelf-life claims, followed by real-time stability studies. The required information includes the study report and its protocol, number of lots, acceptance criteria and testing intervals, the accelerated method where applicable, and conclusions and claimed shelf life.

Section 6.3.2 concerns one lot reflecting actual routine use, whether real or simulated. It calls for the study report, including protocol, acceptance criteria and testing intervals, and conclusions and claimed in-use stability. For automated instrumentation, supporting data are included if calibration stability is claimed. Do not turn that conditional statement into a calibration-study requirement for every product.

Section 6.3.3 concerns one lot evaluated against anticipated shipping conditions. Studies may be real and/or simulated and must include variable conditions such as extreme heat and/or cold. Documentation includes the report with protocol and acceptance criteria, the method used for simulated conditions, and the conclusion and recommended shipping conditions.

Annex I, Section 9.2 separately states that device performance characteristics must be maintained during the manufacturer-indicated lifetime. This article uses that provision only as lifetime-performance context; it does not supply clinical methods or a study protocol.

Avoid a single approval field that obscures what was decided. In this exercise, label release for use, acceptance of a count explanation, application of stability evidence and final product disposition have separate references. A decision can support its own subject without answering the others. LR-144, for example, does not close EX-31, EX-32 or EX-33.

Accountability means naming who will resolve the question and who can make the corresponding decision under the organization's procedures. The example's role labels are placeholders for actual assignments. For a handover, add the named owner, current action, expected response point and the source record that will demonstrate resolution. None of those fields creates a universal signature requirement.

FD-144 is only a reserved reference. There is no completed product disposition record in the retrieved material. Keep that state distinct from a missing historical decision: one may be work not yet performed, while the other may be an existing record that cannot be found. DR-144 is currently a missing cross-reference; FD-144 is a pending decision.

When new evidence arrives, reassess only the conclusions it supports. Finding DR-144 would not automatically explain the plate difference or resolve the label sample. Likewise, correcting an association in LI-144 would need its own explanation and would not create a product disposition. Closure should be a reasoned change in the evidence state, not simply removal of an exception from the list.

Separate internal lot relationships from device-identification records and supply-chain party identities. A kit lot, a component lot, a document revision and a consignee reference are different kinds of identifier. Retain their meanings instead of putting them into a single field called traceability.

21 CFR 820.35(c) requires the UDI to be recorded for each medical device or batch of medical devices. That is a device-or-batch record provision, distinct from the labeling and packaging accuracy controls in Section 820.45. It is not an instruction in this provision to assign a UDI to every input component. For this exercise, point to the applicable device-identification record rather than inventing a UDI value.

For the EU branch, IVDR Article 22(2) concerns identifying direct supply-chain parties to the competent authority: economic operators supplied, economic operators supplying the operator, and directly supplied health institutions or healthcare professionals. Those party-identification obligations should not be presented as a universal component-genealogy mandate.

Article 24(7) requires the manufacturer to keep an up-to-date list of assigned UDIs as part of Annex II technical documentation. Article 24(8) makes economic-operator UDI storage conditional on the devices belonging to categories or groups determined by the specified measure. Do not restate that conditional provision as an unconditional storage duty for every operator and every device.

The practical index can link all three evidence families without equating them. For SH-144, preserve the planned recipient reference and draft state. If dispatch later occurs, retrieve the executed distribution record and its actual quantities and party identity. Until then, neither the planning reference nor the internal component chain demonstrates that any party received these kits.

Give each evidence family a record owner and an authoritative location. The dossier owner maintains the map and its status explanations; source owners remain responsible for their underlying records. This avoids the quiet creation of a second, conflicting history in a shared folder.

In the example, Production owns BR-214, AR-144 and RC-144; Materials owns CI-144; Document Control owns CA-144 and the controlled insert reference. Packaging owns the inspection and sample association, while the labeling owner owns LR-144. The stability and dating owners distinguish SR-52 from DR-144. Logistics owns SH-144, and the disposition owner is accountable for the eventual FD-144 decision.

A useful handover identifies the dossier version or dated snapshot, the scope reviewed, the stable source locations and the unresolved questions. If an export is supplied, identify which authoritative record and revision it represents. Receiving a copy should not silently transfer authority to alter the source, and a newer export should not erase the evidence state previously used for a decision.

• Confirm that the recipient can open the references, not merely see their filenames.
• Read back E05, E07, E10 and E11, including their different unresolved states.
• Assign EX-31, EX-32 and EX-33 to named owners with a clear next action.
• Preserve the distinction between SH-144's draft allocation and an executed shipment.
• Agree how new evidence will be added and how changed conclusions will be explained.

Test one reference during handover. Ask the incoming owner to retrieve LS-144 from E07, state the revision shown and find the associated exception. If that takes an undocumented detour through someone else's memory, improve the index. The objective is reproducible retrieval by another authorized person, not dependence on the person who assembled the dossier.

These arrangements can be implemented with controlled paper or electronic records. This article does not assume a particular application, integration or automated workflow. The evidence question remains the same: can the recipient establish which record they have, what it supports and who owns the next decision?

Run the retrieval in both directions using the same evidence set. Record the starting key, requested question, sources opened, relationships established and unresolved stops. A search that finds a document is not complete until the document's relevance to the question is demonstrated. Timing can help identify awkward handoffs, but no time target is prescribed here.

Backward Retrieval From the Shipment Reference

Begin with SH-144 and ask what evidence supports the allocated kits. Confirm that it is a draft for 180 kits from K-261016, not proof of dispatch. Retrieve AR-144 for the reported 240-kit assembly, then follow the input entries to R-261014, PL-610 and CT-611. Open CA-144 to establish the assigned revision, LR-144 for label release, and LI-144 with LS-144 for the observed mismatch. Stop explicitly at the missing DR-144 reference rather than substituting SR-52.

Forward Retrieval From the Plate Lot

Begin with PL-610 and ask where the issued units are accounted for within this exercise. CI-144 and AR-144 connect it to K-261016. RC-144 accounts for 240 assembled plates, four returned plates and one rejected plate, leaving one of 246 issued plates unexplained. Follow K-261016 to SH-144, but report only the draft allocation. This bounded exercise does not establish that no other kit lots used PL-610; an exhaustive search would need an explicitly defined population and its source records.

The final retrieval note should be short and exact: the three input identities connect to K-261016; 240 kits are reported assembled; one PL-610 unit is unexplained; the retained label sample conflicts with the assigned revision; DR-144 is not retrieved; FD-144 is pending; and SH-144 is a draft allocation, with all 240 kits still on hand. That is a defensible handover of the evidence state—not a release guarantee.